Anthracycline Cardiotoxicity: The Role of Cardio-Oncology in Management
September 18, 2012: Raymond Russell, MD, PhD
▶︎
Advances in Surgical Oncology
▶︎
Cardio-Oncology in 2019
▶︎
Drugs for Heart Failure
▶︎
Survivorship Series: Unraveling Fear of Cancer Recurrence: Realities and Tools for Coping
▶︎
Intro to Cardio-Oncology (Barry Trachtenberg, MD) June 17, 2020
▶︎
ASCO 2026: Research Findings
▶︎
Late Effects of Cancer Treatment: Managing Cardiac Toxicity
▶︎
Advancements in Surgery for Breast Cancer
▶︎
Together Against Melanoma: An Educational Symposium for Patients and Caregivers
▶︎
Improving Transdermal Fentanyl Prescribing
▶︎
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
▶︎
Anthracyclines: The Most Useful and Probably Most Hated Drugs in Treating Cancer Patients
▶︎
Leukemia Awareness Part II
▶︎
Survivorship Series: Exercise After Cancer: Turning Guidelines Into Real Life
▶︎
Medicine Grand Rounds: "Cardio-Oncology: A New Frontier" 1/31/2023
▶︎
KRAS Mutations in Lung Cancer: Novel Therapeutic Approaches | Dr Kathryn Arbour, MSKCC
▶︎
Engineering & Manufacture of Second Generation ADCs: Tools & Techniques - A Webinar hosted by Lonza
▶︎
Cardiovascular Disease Among Survivors of Breast Cancer
▶︎
Cardio-Oncology: What do we know beyond anthracycline cardiotoxicity, Dr. Lili Zhang
▶︎